Skip to main content
Journal cover image

Correction: Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT.

Publication ,  Journal Article
Marsh, RA; Leiding, JW; Logan, BR; Griffith, LM; Arnold, DE; Haddad, E; Falcone, EL; Yin, Z; Patel, K; Arbuckle, E; Bleesing, JJ; Sullivan, KE ...
Published in: J Clin Immunol
November 2020

The original version of this article unfortunately contained the missing author, Caridad Martinez. The authors would like to correct the list. We apologize for any inconvenience that this may have caused. The correct author list is shown above.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Immunol

DOI

EISSN

1573-2592

Publication Date

November 2020

Volume

40

Issue

8

Start / End Page

1211 / 1213

Location

Netherlands

Related Subject Headings

  • Immunology
  • 3204 Immunology
  • 1107 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Marsh, R. A., Leiding, J. W., Logan, B. R., Griffith, L. M., Arnold, D. E., Haddad, E., … submitted on behalf of the Primary Immune Deficiency Treatment Consortium, . (2020). Correction: Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT. J Clin Immunol, 40(8), 1211–1213. https://doi.org/10.1007/s10875-020-00852-0
Marsh, Rebecca A., Jennifer W. Leiding, Brent R. Logan, Linda M. Griffith, Danielle E. Arnold, Elie Haddad, E Liana Falcone, et al. “Correction: Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT.J Clin Immunol 40, no. 8 (November 2020): 1211–13. https://doi.org/10.1007/s10875-020-00852-0.
Marsh RA, Leiding JW, Logan BR, Griffith LM, Arnold DE, Haddad E, et al. Correction: Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT. J Clin Immunol. 2020 Nov;40(8):1211–3.
Marsh, Rebecca A., et al. “Correction: Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT.J Clin Immunol, vol. 40, no. 8, Nov. 2020, pp. 1211–13. Pubmed, doi:10.1007/s10875-020-00852-0.
Marsh RA, Leiding JW, Logan BR, Griffith LM, Arnold DE, Haddad E, Falcone EL, Yin Z, Patel K, Arbuckle E, Bleesing JJ, Sullivan KE, Heimall J, Burroughs LM, Skoda-Smith S, Chandrakasan S, Yu LC, Oshrine BR, Cuvelier GDE, Thakar MS, Chen K, Teira P, Shenoy S, Phelan R, Forbes LR, Martinez C, Chellapandian D, Dávila Saldaña BJ, Shah AJ, Weinacht KG, Joshi A, Boulad F, Quigg TC, Dvorak CC, Grossman D, Torgerson T, Graham P, Prasad V, Knutsen A, Chong H, Miller H, de la Morena MT, DeSantes K, Cowan MJ, Notarangelo LD, Kohn DB, Stenger E, Pai S-Y, Routes JM, Puck JM, Kapoor N, Pulsipher MA, Malech HL, Parikh S, Kang EM, submitted on behalf of the Primary Immune Deficiency Treatment Consortium. Correction: Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT. J Clin Immunol. 2020 Nov;40(8):1211–1213.
Journal cover image

Published In

J Clin Immunol

DOI

EISSN

1573-2592

Publication Date

November 2020

Volume

40

Issue

8

Start / End Page

1211 / 1213

Location

Netherlands

Related Subject Headings

  • Immunology
  • 3204 Immunology
  • 1107 Immunology